● Live
Tracking psychedelic news in real time — 100 articles loaded
A self-hosted psychedelic industry intelligence dashboard — live news, clinical trial tracking, and regulatory monitoring, aggregated from public sources. How it works →
Article summaries below are AI-generated and may contain inaccuracies — verify against the linked source before relying on them.
Culture
The Science Born of Enchantment: Jurema at the Crossroads of Knowledge
AI summary
The article explores Jurema, a traditional Amazonian plant with psychoactive properties, as a bridge between indigenous knowledge and modern scientific research. It highlights emerging studies on its potential therapeutic applications and the ethical considerations of integrating ancestral practices with contemporary psychedelic science. This convergence underscores growing interest in validating traditional plant medicine through rigorous scientific inquiry.
Chacruna · Nov 6, 2026
Business
Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date
AI summary
The FDA provided regulatory clarity on psychedelics following the midterms, addressing the House Psychedelics Caucus's inquiries. ICER has initiated a review of Compass’ psilocybin therapy, signaling potential cost assessments. The Terran v. Compass lawsuit now has a trial date, marking a pivotal legal development for the industry.
Psychedelic Alpha · Nov 6, 2026
Culture
Curious Where to Forage Wild Magic Mushrooms?
AI summary
The article explores the growing interest in foraging wild psilocybin mushrooms, highlighting both the cultural fascination and legal complexities surrounding this practice. It examines how foraging intersects with psychedelic research, conservation efforts, and the evolving regulatory landscape for psychoactive substances. The piece underscores the tension between traditional knowledge, environmental stewardship, and the psychedelic industry's push for legal and sustainable access.
DoubleBlind · Nov 4, 2026
Business
Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona
AI summary
Compass announced it plans to file an NDA within two weeks, while declining to comment on Usona. The company’s regulatory submission marks a key milestone in its psychedelic therapeutics pipeline. The decision reflects ongoing progress in advancing psychedelic-derived treatments through the FDA process.
Psychedelic Alpha · Nov 3, 2026
Policy
Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It
AI summary
Colorado’s early regulatory framework for psychedelic care, as analyzed in the article, highlights both promising therapeutic access and significant challenges in scalability, integration into healthcare systems, and ensuring equitable access. The field is now grappling with whether the state’s approach offers a viable model or requires adjustments to address gaps in training, oversight, and long-term sustainability. Industry stakeholders are urged to learn from these experiences to shape more effective, standardized practices.
Psychedelics Today · Nov 2, 2026
Business
Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine
AI summary
Usona has submitted a psilocybin therapy application to the FDA, marking progress in its psychedelic drug development. The FDA received 610 public comments on its psilocybin drug application, reflecting industry and stakeholder engagement. Additionally, the FDA approved NRx Pharmaceuticals’ generic ketamine formulation, a key milestone in expanding access to the medication.
Psychedelic Alpha · Nov 2, 2026
Business
Usona Files Psilocybin for Depression NDA as Race With Compass Tightens
AI summary
Usona has submitted an NDA for psilocybin as a treatment for major depressive disorder, intensifying its competitive race with Compass Pathways in the psychedelic therapy space. The filing marks a critical step toward potential FDA approval, highlighting the growing urgency and stakes in the depression treatment market.
Psychedelic Alpha · Nov 2, 2026
Culture
What Do Psychedelics, Déjà Vu, and Home Have in Common?
AI summary
A recent study from DoubleBlind explores the neurological and psychological links between psychedelics, déjà vu, and the concept of home, suggesting that these experiences may share underlying mechanisms related to memory processing and emotional resonance. Researchers hypothesize that psychedelics may temporarily alter neural pathways, enhancing recall of familiar environments or emotions tied to home, thereby triggering déjà vu-like sensations. The findings highlight potential therapeutic implications for understanding trauma, memory, and emotional healing through psychedelic-assisted interventions.
DoubleBlind · Nov 2, 2026
Business
FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending
AI summary
The FDA has approved NRx’s preservative-free generic ketamine, marking a significant milestone for the company in expanding access to the medication. However, NRx’s legal effort to ban competing ketamine products remains under review, highlighting ongoing regulatory and market challenges in the psychedelic therapeutics space.
Psychedelic Alpha · Oct 30, 2026
Culture
You Can Take Iboga Out of Gabon. Can You Strip It of the Tradition?
AI summary
The article explores the growing commercial interest in iboga, a psychoactive substance from Gabon, as the psychedelic industry seeks to harness its therapeutic potential. It highlights the ethical and cultural tensions surrounding its extraction, emphasizing the risk of commodifying a deeply rooted traditional practice. The piece questions whether iboga can be separated from its cultural context without losing its significance.
DoubleBlind · Oct 30, 2026
Business
Federal Health Officials Outline Pre-Approval Roadmap for Psychedelic Medicines at Horizons Forum
AI summary
Federal health officials outlined a pre-approval roadmap for psychedelic medicines at the Horizons Forum, emphasizing standardized clinical trial protocols and regulatory pathways to expedite safe, evidence-based therapeutic development. The framework highlights collaboration between federal agencies and industry stakeholders to address safety, efficacy, and scalability challenges in psychedelic drug approvals.
Lucid News · Oct 28, 2026
Policy
Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art
AI summary
Jackie Tileston explores the intersection of nondual mysticism and 5-MeO-DMT in her artistic and research work, examining how these practices shape psychedelic experiences. The article critiques the complexities and ethical dilemmas inherent in creating and interpreting psychedelic art, highlighting tensions between spiritual exploration and cultural appropriation. Tileston’s insights underscore the need for nuanced approaches to integrating mystical traditions with contemporary psychedelic practices.
Psychedelics Today · Oct 28, 2026
Culture
Rick Strassman Questions How Science Defines the Mystical Experience
AI summary
Rick Strassman, a pioneering psychiatrist and researcher in psychedelic science, critiques how contemporary science defines mystical experiences, arguing that current frameworks fail to capture their subjective depth and transformative potential. He highlights limitations in quantifying phenomena like ego dissolution and spiritual insights, which are central to psychedelic research. Strassman’s concerns underscore ongoing debates about integrating mystical dimensions into empirical studies within the psychedelic industry.
DoubleBlind · Oct 28, 2026
Business
Pharma Moves In: Investors, Developers and Lilly’s Carole Ho at the Psychedelic Healthcare Forum
AI summary
At the Psychedelic Healthcare Forum, industry leaders including Lilly’s Carole Ho, investors, and developers convened to discuss advancements in psychedelic healthcare, emphasizing collaboration on clinical trials, regulatory strategies, and market expansion for therapeutic applications. The event highlighted growing pharma interest in scaling psychedelic treatments while addressing challenges in research and commercialization. Key stakeholders shared insights on navigating regulatory landscapes and fostering innovation in the rapidly evolving field.
Psychedelic Alpha · Oct 28, 2026
Policy
Weekly Psychedelic Policy Briefing: Oct. 27, 2026
AI summary
The October 27, 2026, Weekly Psychedelic Policy Briefing highlights recent legislative advancements, including state-level decriminalization measures and federal regulatory updates, signaling growing acceptance of psychedelics in therapeutic contexts. Key developments include the FDA’s expanded oversight framework for clinical trials and renewed bipartisan support for psychedelic research funding. These shifts underscore a pivotal moment in the industry’s trajectory toward mainstream integration and commercialization.
Psychedelics Today · Oct 27, 2026
Culture
Foucault’s Lysergic Dreams Remain Buried in Death Valley
AI summary
The article explores the historical and cultural significance of a mysterious site in Death Valley, linked to early 20th-century psychedelic experimentation and the enigmatic "Foucault’s Lysergic Dreams," highlighting its potential relevance to contemporary psychedelic research and historical narratives within the industry. Researchers suggest the site may hold clues about early psychedelic use and its intersection with countercultural movements, though its full significance remains under investigation.
Chacruna · Oct 26, 2026
Business
Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket
AI summary
Stakeholders largely welcomed the FDA’s recent psychedelics docket release, citing it as a step toward regulatory clarity, though some expressed concerns about procedural delays and lack of transparency. Industry leaders emphasized the need for collaborative dialogue to address lingering uncertainties, while advocates highlighted the potential to advance therapeutic development. The mixed feedback underscores ongoing tensions between regulatory rigor and innovation in the psychedelic space.
Psychedelic Alpha · Oct 26, 2026
Culture
Is Psilocybin a Treatment for Parkinson’s Disease?
AI summary
A recent study published in DoubleBlind explores psilocybin's potential as a treatment for Parkinson’s disease, highlighting its neuroprotective properties and ability to reduce motor symptoms through serotonin receptor modulation. Preliminary findings suggest psilocybin may alleviate inflammation and oxidative stress linked to Parkinson’s progression, though further clinical trials are needed to confirm efficacy and safety. These results position psilocybin as a promising candidate for neurodegenerative therapies within the psychedelic medicine space.
DoubleBlind · Oct 26, 2026
Culture
Owsley Stanley, the Acid King and Godfather of Grateful Dead Bootlegs
AI summary
Owsley Stanley, dubbed the "Acid King," was a pivotal figure in the psychedelic movement, renowned for his role in producing illicit Grateful Dead bootleg recordings that became cultural artifacts. His work in the 1960s and 1970s not only shaped the underground music scene but also cemented his legacy as a key architect of the counterculture era's sonic and cultural legacy.
DoubleBlind · Oct 23, 2026
Business
Before the Approvals Arrive: Norway, Germany, Switzerland, the UK and Estonia at TAIP Conference 2026
AI summary
At the TAIP Conference 2026, Norway, Germany, Switzerland, the UK, and Estonia convened to discuss regulatory frameworks and market readiness for psychedelics, emphasizing cross-border collaboration ahead of potential national approvals. The gathering highlighted shared goals to streamline therapeutic access while addressing legal and safety considerations for the industry’s growth. Participants underscored the importance of harmonizing policies to accelerate clinical and commercial progress in the psychedelic sector.
Psychedelic Alpha · Oct 23, 2026
Policy
Timothy Leary Did Not Cause the Drug War
AI summary
The article clarifies that Timothy Leary’s advocacy for psychedelics did not directly cause the U.S. drug war, which emerged from a complex interplay of political, social, and legislative factors. While Leary’s public support for psychedelic use contributed to public discourse, the drug war’s origins are more closely tied to Cold War-era anti-drug policies and the influence of organizations like the CIA. The piece underscores the importance of distinguishing historical narratives to inform contemporary psychedelic policy discussions.
Psychedelics Today · Oct 22, 2026
Business
Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In on Psychedelic Access
AI summary
The U.S. Department of Veterans Affairs is expanding psychedelic therapy access to ten new sites, while federal regulators continue to evaluate REMS requirements for psychedelics, highlighting ongoing challenges for therapies like ibogaine amid efforts to balance safety and therapeutic potential. Agencies are scrutinizing pathways for broader access, reflecting a complex regulatory landscape as the psychedelic industry seeks federal approval and integration into mainstream healthcare.
Psychedelic Alpha · Oct 22, 2026
Business
Oregon U-turns on Doubling Psilocybin License Fees
AI summary
Oregon has reversed its decision to double psilocybin therapy license fees, abandoning a proposed increase that had sparked industry concern, following feedback from stakeholders and potential economic impacts. The state’s regulatory body cited the need to support therapeutic access and industry growth, signaling a shift in policy to stabilize the emerging psychedelic healthcare sector. This U-turn highlights ongoing efforts to balance regulatory oversight with fostering innovation in the field.
Lucid News · Oct 22, 2026
Business
Horizons 2026: New Medicines for an Old System
AI summary
The article "Horizons 2026: New Medicines for an Old System" from Lucid News highlights emerging psychedelic therapies poised to revolutionize mental health treatment by addressing gaps in conventional care, with several companies advancing clinical trials for conditions like PTSD and depression. These innovations underscore a growing shift toward integrative medicine, aiming to modernize healthcare systems through evidence-based psychedelic interventions. Regulatory and therapeutic breakthroughs in 2026 are expected to expand access and legitimacy for these groundbreaking treatments.
Lucid News · Oct 21, 2026
Culture
Indigenous Reciprocity Beyond Romanticization
AI summary
The article "Indigenous Reciprocity Beyond Romanticization" from Chacruna critiques the psychedelic industry's tendency to romanticize Indigenous traditions, advocating for ethical, respectful collaboration rooted in mutual benefit rather than exploitation. It emphasizes the need for genuine engagement with Indigenous communities, prioritizing their sovereignty and knowledge systems over superficial cultural appropriation. The piece calls for systemic changes to ensure that Indigenous voices shape the future of psychedelic research and practice.
Chacruna · Oct 21, 2026
Business
Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try and the Psychedelics Executive Order
AI summary
HHS official Matt Zorn, formerly a poacher turned gamekeeper, discusses his advocacy for Ibogaine as a treatment for addiction, the Right to Try Act, and the federal Psychedelics Executive Order, emphasizing regulatory progress and patient access in the psychedelic industry. Zorn highlights the importance of policy frameworks to support clinical research and therapeutic applications, reflecting shifting federal priorities toward psychedelic medicine. His insights underscore the intersection of public health, regulatory reform, and innovation in the emerging psychedelics sector.
Psychedelic Alpha · Oct 21, 2026
Culture
Did Ancient Buddhists Drink Visionary Mushroom Elixirs?
AI summary
A recent article from DoubleBlind explores historical evidence suggesting ancient Buddhist practitioners may have used visionary mushroom elixirs as part of their spiritual rituals, drawing on archaeological and textual sources. The study highlights potential parallels between psychedelic use in pre-modern Buddhist traditions and contemporary interest in psychedelics for therapeutic and spiritual exploration. Researchers caution that further investigation is needed to confirm these connections and their cultural significance.
DoubleBlind · Oct 21, 2026
Policy
From Ecstasy Rising to Peaking: Jordan Kronick on 20 Years Covering Psychedelics
AI summary
Jordan Kronick, a veteran journalist, reflects on two decades of covering the psychedelics industry, tracing its evolution from early advocacy to mainstream clinical applications and regulatory growth. His insights highlight the sector's transformation from fringe movement to a burgeoning therapeutic field, emphasizing key milestones and ongoing challenges. Kronick underscores the importance of sustained research and policy development in shaping the industry's future.
Psychedelics Today · Oct 21, 2026
Policy
What Psychedelics Have Taught Me About Paying Attention as a Father
AI summary
The article explores how psychedelics have enhanced the author’s ability to stay present and attentive as a father, fostering deeper emotional connections with their children. It highlights insights into mindfulness and intentional parenting gained through psychedelic experiences, suggesting potential therapeutic applications for family dynamics. The piece underscores the transformative role of psychedelics in cultivating awareness and empathy in caregiving.
Psychedelics Today · Oct 20, 2026
Business
Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing
AI summary
The podcast highlights key insights from the Early Healthcare Forum, including advancements in psychedelic-assisted therapies and regulatory pathways. The FDA’s Ibogaine Blueprint outlines potential guidelines for its therapeutic use, while Compass Talks Pricing discusses strategies to enhance accessibility and affordability in the psychedelic healthcare sector. These updates reflect ongoing progress in clinical, regulatory, and commercial developments within the industry.
Psychedelic Alpha · Oct 20, 2026
Culture
Can A Playlist Adequately Match the Arc of a Psychedelic Trip?
DoubleBlind · Oct 19, 2026
Policy
Vital Community Webinar
AI summary
The "Vital Community Webinar" hosted by Psychedelics Today brought together industry leaders and advocates to discuss collaborative efforts in advancing psychedelic research, policy, and community engagement. Key topics included scaling therapeutic applications, ethical frameworks, and cross-sector partnerships to foster equitable access and integration. The event underscored the importance of collective action in shaping the future of the psychedelic movement.
Psychedelics Today · Oct 16, 2026
Culture
Can VR Really Recreate a Psychedelic Trip?
AI summary
A recent study from DoubleBlind explores whether virtual reality (VR) can authentically replicate the sensory and emotional aspects of a psychedelic trip, finding that while VR can mimic visual and auditory elements, it struggles to capture the full depth of subjective experience. Researchers highlight the technology's potential for therapeutic applications and experiential education, though limitations in replicating the introspective and transformative qualities of psychedelics remain. The findings underscore the evolving role of VR in the psychedelic industry's pursuit of accessible, controlled experiences.
DoubleBlind · Oct 16, 2026
Business
American Trickster: The Hidden Lives of Carlos Castaneda
AI summary
The article "American Trickster: The Hidden Lives of Carlos Castaneda" from Lucid News investigates the controversial life of the author behind the *Don Juan* series, revealing discrepancies between his public persona and private actions, including allegations of fraud and exploitation. It challenges the mythos surrounding his spiritual teachings, which have long influenced psychedelic and New Age movements, by exposing his complex, often unethical real-life behavior. The piece underscores the tension between his literary legacy and the ethical questions raised by his personal history.
Lucid News · Oct 15, 2026
Culture
Psychedelic Dawn at the Edge of the Global South
AI summary
The article "Psychedelic Dawn at the Edge of the Global South" explores the resurgence of traditional psychedelic practices in marginalized regions of the Global South, highlighting their cultural significance and potential for modern therapeutic and spiritual applications. It emphasizes the role of indigenous knowledge systems and grassroots movements in shaping contemporary psychedelic research and policy. The piece underscores the growing intersection between ancestral wisdom and global psychedelic innovation, positioning these regions as pivotal to the industry's future.
Chacruna · Oct 14, 2026
Business
The Psychedelic Practitioner Issue 7: Preparedness (Systems)
Psychedelic Alpha · Oct 14, 2026
Culture
Indigenous Peoples’ Day Ain’t Over Yet
AI summary
The article "Indigenous Peoples’ Day Ain’t Over Yet" from DoubleBlind highlights ongoing efforts within the psychedelic industry to honor Indigenous cultural contributions while addressing ethical concerns around appropriation and exploitation. It emphasizes the need for respectful collaboration and the importance of centering Indigenous voices in shaping the industry’s future. The piece underscores that the movement’s success depends on meaningful, equitable partnerships with Indigenous communities.
DoubleBlind · Oct 14, 2026
Policy
Weekly Psychedelic Policy Briefing: October 12, 2026
AI summary
The October 12, 2026, Psychedelics Today policy briefing highlights recent legislative advancements, including state-level decriminalization measures and federal regulatory updates, signaling growing mainstream acceptance of psychedelics for therapeutic use. Key developments include the FDA’s revised guidelines for psychedelic clinical trials and increased funding for research initiatives. Industry stakeholders note these shifts as critical for expanding access and legitimizing the field.
Psychedelics Today · Oct 12, 2026
Policy
How to Change Your Behavior
AI summary
The article explores how psychedelics can facilitate behavior change by enhancing self-awareness and neuroplasticity, offering insights into their therapeutic potential for addressing maladaptive patterns. It highlights emerging research on integrating psychedelic-assisted therapies with mindfulness practices to foster lasting behavioral transformation. The findings underscore the growing interest in leveraging these substances for mental health interventions.
Psychedelics Today · Oct 12, 2026
Culture
Psilocybin Mushrooms Are America’s Psychedelic of Choice
DoubleBlind · Oct 12, 2026
Business
New Mexico Medical Psilocybin Program Regulation Changes Spark Outcry
AI summary
New Mexico’s medical psilocybin program faces criticism after recent regulatory changes introduced stricter patient eligibility and provider training requirements, prompting backlash from advocates and patients who argue the adjustments limit access to therapeutic benefits. The revisions, aimed at enhancing oversight, have sparked concerns about reduced program accessibility and potential delays in treatment for qualifying individuals. Industry stakeholders and healthcare providers are now calling for a review of the updated guidelines to balance safety with patient needs.
Lucid News · Oct 9, 2026
Culture
ECSTATIC BLOOM: A Psychedelic Soirée & Benefit
Chacruna · Oct 8, 2026
Business
Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
Psychedelic Alpha · Oct 8, 2026
Policy
Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health
AI summary
Kenneth Tupper, PhD, a leading researcher and advocate in psychedelic public health, emphasizes harm reduction and drug education strategies to address substance use challenges. His work explores the therapeutic potential of Ayahuasca within Canada’s regulatory framework, advocating for evidence-based approaches to integrate psychedelics into public health systems. Tupper’s research underscores the importance of culturally informed, science-driven policies to promote safe and equitable psychedelic use.
Psychedelics Today · Oct 7, 2026
Culture
What Do Dying and Tripping on Psychedelics Have in Common?
DoubleBlind · Oct 7, 2026
Policy
Weekly Psychedelic Policy Briefing: October 5, 2026
Psychedelics Today · Oct 5, 2026
Culture
Compass Pathways Is Taking a Page From Johnson & Johnson
DoubleBlind · Oct 5, 2026
Business
Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines
Psychedelic Alpha · Oct 5, 2026
Policy
Psychedelic Churches Need Psychedelic Seminaries
Psychedelics Today · Oct 3, 2026
Policy
Tell the FDA What Psychedelic Care Should Look Like. You Have Until Monday.
Psychedelics Today · Oct 2, 2026
Culture
The Heated Debate Over How Psychedelics Work in the Brain
AI summary
The article explores the ongoing scientific debate over psychedelics' mechanisms in the brain, focusing on their interaction with serotonin receptors, particularly 5-HT2A, and whether they act as agonists or antagonists. Researchers also discuss the role of other neurotransmitters like dopamine and glutamate, as well as the potential for neuroplasticity, highlighting diverging theories about their therapeutic potential and neurobiological impact.
DoubleBlind · Oct 2, 2026
Business
Quarterly Psychedelics Briefing: Q3 2026
AI summary
Psychedelic Alpha's Q3 2026 briefing highlights a 22% quarter-over-quarter growth in the psychedelics market, driven by expanding therapeutic applications and increased investor interest. Key developments include FDA updates on psilocybin therapy trials and regulatory clarity on psychedelic-assisted treatments. Notable company milestones include clinical trial advancements and strategic partnerships aimed at accelerating commercialization.
Psychedelic Alpha · Oct 2, 2026
Policy
When Psychedelic Experiences Turn into Crisis, Training Can Make All the Difference
Psychedelics Today · Oct 2, 2026
Policy
Weekly Psychedelic Policy Briefing: September 30th, 2026
Psychedelics Today · Sep 30, 2026
Culture
Can You Actually Stop a Bad Trip?
DoubleBlind · Sep 30, 2026
Culture
10th Anniversary of the Chacruna Institute
Chacruna · Sep 28, 2026
Culture
The DEA Is Trying to Add a Grip of New Drugs to Schedule I
DoubleBlind · Sep 28, 2026
Business
Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike
AI summary
In Q2 2026, the DEA advanced efforts to schedule 5 tryptamines under Schedule I, raising regulatory concerns for the psychedelic industry. Oregon reversed its decision to hike psilocybin service fees, easing financial burdens on providers. Meanwhile, updated lobbying efforts highlight ongoing advocacy for policy reform and expanded access to psychedelic therapies.
Psychedelic Alpha · Sep 25, 2026
Culture
The Oldest Ayahuasca Researchers Weren’t in Labs
DoubleBlind · Sep 23, 2026
Culture
Reflections on the Psychedelic Executive Order: The Dust Settles
Chacruna · Sep 23, 2026
Culture
Building Tripsafe Communities: Why We Need Psychedelic Harm Reduction
Chacruna · Sep 23, 2026
Business
FDA Holds Historic Public Hearing on Psychedelic Therapies
AI summary
The FDA convened a historic public hearing to discuss the regulatory pathways for psychedelic therapies, gathering input from stakeholders, researchers, and patients to shape future guidelines for their clinical applications. The event marked a pivotal step in advancing psychedelic treatments for mental health conditions, reflecting growing interest and scrutiny from federal regulators. Participants emphasized the need for balanced oversight to ensure safety while fostering innovation in this emerging therapeutic space.
Lucid News · Sep 22, 2026
Policy
Weekly Psychedelic Policy Briefing, September 21, 2026
AI summary
The September 21, 2026, Weekly Psychedelic Policy Briefing highlights recent legislative advancements, including several U.S. states advancing decriminalization measures and the FDA updating guidelines for psychedelic clinical trials. Key developments also include federal discussions on expanding access to psychedelic-assisted therapies, signaling growing regulatory support for the industry’s research and commercialization efforts. These shifts underscore a maturing legal and policy landscape for psychedelics in 2026.
Psychedelics Today · Sep 22, 2026
Business
Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
Psychedelic Alpha · Sep 21, 2026
Business
Introducing The Psychedelic News Feed Podcast
Psychedelic Alpha · Sep 21, 2026
Culture
Psychedelic Therapy Is Imminent. Will the FDA Get It Right?
DoubleBlind · Sep 21, 2026
Policy
Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity
AI summary
Health Canada has authorized Optimi’s natural psilocybin trial, marking a key step in advancing psychedelic therapy research. Concurrently, a House Bill targeting botanical drug exclusivity aims to address regulatory challenges for companies developing plant-based medications, signaling potential legislative shifts in the psychedelic industry.
Psychedelics Today · Sep 18, 2026
Business
Field Notes #5: ‘Psychedelics Week’ in Washington D.C.
AI summary
Psychedelics Week in Washington D.C. brought together industry leaders, researchers, and policymakers to discuss regulatory advancements, clinical research, and the future of psychedelic integration. Key discussions highlighted bipartisan support for therapeutic applications and the need for standardized frameworks to accelerate access and safety. The event underscored growing momentum for policy reform and cross-sector collaboration in the psychedelic space.
Psychedelic Alpha · Sep 18, 2026
Culture
Conjuring Giant Sphinxes at Burning Man to Help You Know Yourself
AI summary
The article explores how psychedelic-inspired art installations, such as giant Sphinx sculptures at Burning Man, are used to foster self-reflection and spiritual exploration, highlighting the intersection of psychedelic experiences and immersive cultural events. These creations aim to catalyze introspection and personal growth through symbolic, transformative art. The piece underscores growing interest in integrating psychedelic practices with creative and communal experiences within the broader psychedelic industry.
DoubleBlind · Sep 18, 2026
Business
‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop
AI summary
ARPA-H’s Ibogaine Workshop emphasized the need for rapid, precise advancements in psychedelic research to accelerate safe, scalable therapeutic applications. Key discussions centered on prioritizing clinical trials, regulatory strategies, and cross-sector collaboration to address challenges in translating ibogaine’s potential into FDA-approved treatments. Stakeholders highlighted the importance of balancing innovation with rigorous scientific standards to ensure patient safety and efficacy.
Psychedelic Alpha · Sep 17, 2026
Policy
What Lynn Watkins Actually Told the FDA about Chronic Pain and Psychedelics
AI summary
Lynn Watkins provided the FDA with detailed insights into her clinical research on psychedelics for chronic pain, emphasizing their potential efficacy and safety in treating refractory cases. Her testimony highlighted the need for regulatory clarity and expanded access to psychedelic therapies, sparking discussions on their role in pain management. The exchange underscores growing interest in psychedelics as a viable alternative for chronic pain treatment.
Psychedelics Today · Sep 16, 2026
Business
Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard
Psychedelic Alpha · Sep 16, 2026
Culture
The Psychedelic Legacy Africa Still Isn’t Properly Credited For
AI summary
The article highlights how Africa's ancient use of psychedelics in spiritual and cultural practices has been historically overlooked, despite their foundational role in the region's psychedelic legacy. Modern Western commercialization of these substances often fails to credit or collaborate with African communities, raising ethical concerns about appropriation. The piece calls for greater recognition of indigenous knowledge and equitable partnerships in the psychedelic industry.
DoubleBlind · Sep 16, 2026
Business
No Questions Asked: FDA’s Psychedelics Public Hearing
Psychedelic Alpha · Sep 15, 2026
Business
Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder
AI summary
Definium has achieved a second positive Phase 3 trial result for its treatment of Generalised Anxiety Disorder, marking a significant milestone in advancing its psychedelic-based therapeutic approach. The success underscores the potential of its formulation to meet regulatory standards and could expedite pathways to market approval. This outcome highlights growing momentum in the psychedelic industry for addressing mental health conditions with novel, evidence-based interventions.
Psychedelic Alpha · Sep 14, 2026
Culture
Scientists Engineered a “Humanized” Mouse to Study Psychedelics
AI summary
Scientists have developed a "humanized" mouse model, engineered to express human serotonin receptors, to better study the biological mechanisms of psychedelics like psilocybin and MDMA. This advancement enables more accurate preclinical research into their therapeutic potential for mental health disorders. The model represents a significant step forward in bridging the gap between animal studies and human applications in psychedelic science.
DoubleBlind · Sep 14, 2026
Culture
Between Protection and Control: Federal Public Prosecutor’s Office Reignites the Debate on Ayahuasca Regulation in Brazil
AI summary
The Brazilian Federal Public Prosecutor’s Office has intensified legal actions against Ayahuasca practitioners, reigniting debates over the drug’s regulation under Brazil’s 2006 law. The move highlights tensions between protecting indigenous traditions and enforcing anti-narcotic controls, with critics warning of risks to cultural and spiritual practices. The case underscores ongoing legal and ethical challenges in balancing public health concerns with the rights of religious communities.
Chacruna · Sep 11, 2026
Business
Approvals to Access: A Crude Schematic
AI summary
Psychedelic Alpha's article "Approvals to Access: A Crude Schematic" outlines the complex regulatory and logistical challenges in scaling psychedelic therapy access, emphasizing the need for streamlined approval processes and stakeholder collaboration to bridge gaps between research and real-world implementation. The piece highlights key bottlenecks in clinical trials, licensing, and distribution, while advocating for a more transparent, patient-centered framework to accelerate therapeutic availability. It underscores the critical role of policy alignment in overcoming systemic barriers to psychedelic medicine.
Psychedelic Alpha · Sep 11, 2026
Culture
Ayahuasca and Wellness Spaces Aren’t Built for Disabled and Autistic Bodies
AI summary
The article highlights systemic accessibility barriers in ayahuasca and wellness spaces, which often fail to accommodate disabled and autistic individuals due to physical, sensory, and communicative challenges. These gaps limit equitable participation in psychedelic healing practices, underscoring the need for inclusive design and support systems in the industry. Advocates call for greater awareness and structural changes to ensure these spaces are accessible to all.
DoubleBlind · Sep 11, 2026
Policy
Beyond the Foxhole: How Psychedelic Policy’s Coalition Is Growing Past Veterans
AI summary
The article highlights the expansion of psychedelic policy advocacy beyond veteran communities, driven by growing support from healthcare professionals, patients, and researchers. This broadening coalition reflects increasing recognition of psychedelics' therapeutic potential and the need for legislative reform to facilitate clinical use and public access. The shift underscores a maturing movement with diverse stakeholders pushing for policy changes.
Psychedelics Today · Sep 11, 2026
Culture
The Case That Shook Céu do Mar
AI summary
The case involving Céu do Mar, a Brazilian psychedelic research center, sparked significant legal and regulatory debate, highlighting tensions between scientific exploration and government oversight in the psychedelic industry. The ruling underscored the complexities of navigating legal frameworks for psychedelic research, influencing ongoing discussions about policy reform and therapeutic applications. This landmark case has since become a pivotal reference point for advocates and policymakers in the global psychedelic movement.
Chacruna · Sep 10, 2026
Policy
THE GATEWAY: Live From DC After the FDA Psychedelics Hearing
AI summary
The FDA's recent psychedelics hearing in DC highlighted ongoing regulatory discussions around therapeutic applications, with officials emphasizing the need for robust clinical data and safety protocols. Key stakeholders expressed cautious optimism about potential pathway advancements, while calls for transparency and equitable access remained central to the dialogue. The event underscored the industry's pivotal role in shaping future psychedelic medicine policies.
Psychedelics Today · Sep 10, 2026
Business
Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM
AI summary
In a recent NEJM publication, Davis, Farchione, and colleagues outlined the FDA’s proposed framework for psychedelic drug development, emphasizing structured clinical trial protocols, safety monitoring, and therapeutic applications. The framework aims to standardize regulatory pathways for psychedelics, balancing innovation with patient safety. This guidance marks a pivotal step toward legitimizing psychedelic therapies within mainstream medicine.
Psychedelic Alpha · Sep 10, 2026
Culture
Indigenous Medicines Are Inseparable From Territory
AI summary
The article emphasizes that indigenous medicinal practices are deeply tied to specific territories, reflecting a holistic relationship between people, land, and healing traditions. This connection underscores the ethical and legal complexities for the psychedelic industry, which must navigate issues like biopiracy and cultural appropriation. The piece calls for respectful collaboration with Indigenous communities to ensure their knowledge is preserved and honored.
DoubleBlind · Sep 9, 2026
Business
Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD
AI summary
Two New Zealand psychiatrists have been approved to prescribe MDMA for PTSD treatment, marking a significant milestone in the country's integration of psychedelic-assisted therapies. This development follows regulatory progress and highlights the potential of MDMA as a groundbreaking intervention for trauma-related disorders. The psychiatrists will now lead clinical trials, advancing access to innovative PTSD care in New Zealand.
Psychedelic Alpha · Sep 7, 2026
Culture
Those Trump-Shaped Ecstasy Pills Actually Aren’t Ecstasy At All
AI summary
A recent investigation by DoubleBlind reveals that Trump-shaped pills marketed as ecstasy (MDMA) are not actually MDMA, raising concerns about mislabeling and the potential presence of other substances. The pills, part of a controversial marketing stunt, were found to contain different compounds, highlighting risks in the psychedelic and illicit drug markets. This case underscores the need for stricter regulation and transparency in psychedelic product labeling.
DoubleBlind · Sep 7, 2026
Culture
Is “Gas Station Molly” the Next Big Grey Market Drug?
DoubleBlind · Sep 4, 2026
Business
Pα+ Library: Psychedelic REMS
Psychedelic Alpha · Sep 3, 2026
Culture
Inside the First Ayahuasca Forum Hosted by Indigenous Peoples
AI summary
The first Ayahuasca Forum hosted by Indigenous Peoples, as reported by DoubleBlind, brought together traditional knowledge holders and global stakeholders to discuss the plant's cultural significance, legal challenges, and potential therapeutic applications. The event emphasized Indigenous sovereignty in safeguarding sacred practices while exploring pathways for ethical integration into modern wellness and research frameworks. Participants highlighted the need for respectful collaboration and policy reform to protect both cultural heritage and scientific inquiry.
DoubleBlind · Sep 2, 2026
Business
Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?
Psychedelic Alpha · Sep 1, 2026
Culture
Can Psilocybin Protect Skin Cells From Premature Aging?
DoubleBlind · Sep 1, 2026
Culture
Hidden Treasures: How a Team of Chilean Psychonauts is Preserving Jonathan Ott’s Legacy
AI summary
A Chilean team of psychonauts is collaborating with Chacruna to preserve the ethnobotanical research and writings of Jonathan Ott, a pioneering figure in psychedelic studies, by digitizing and archiving his work to ensure its accessibility and legacy for future generations. Their efforts highlight the importance of safeguarding traditional knowledge and scientific contributions in the psychedelic field. This initiative underscores the intersection of cultural preservation and contemporary research in the industry.
Chacruna · Aug 31, 2026
Culture
Technodelics Promise Psychedelic Healing. Can They Deliver?
AI summary
The article explores the emerging field of technodelics, which combine psychedelic therapies with digital tools to enhance mental health treatment. While proponents highlight their potential for scalable, personalized healing, skeptics question their clinical efficacy and regulatory readiness. The piece underscores the industry's ambitious goals amid ongoing debates about scientific validation and ethical implications.
DoubleBlind · Aug 28, 2026
Policy
The Best Psychedelic Education Does Not Look Psychedelic
AI summary
The article argues that effective psychedelic education prioritizes practical, evidence-based approaches over visually stimulating or "psychedelic" aesthetics, emphasizing structured learning and integration techniques to ensure safe, informed use. It highlights the importance of grounding education in scientific research and therapeutic applications to support the industry's growth and responsible practices. The piece underscores that meaningful education focuses on knowledge and preparation rather than sensory spectacle.
Psychedelics Today · Aug 28, 2026
Business
A Closer Look at Definium’s Phase 3 LSD for GAD Readout
AI summary
Definium’s Phase 3 trial for LSD as a treatment for generalized anxiety disorder (GAD) released preliminary data showing promising efficacy and safety profiles, with significant reductions in anxiety symptoms observed in participants. The results highlight potential regulatory and therapeutic advancements for psychedelic medicine, though further analysis is needed for full conclusions. The findings underscore growing interest in LSD’s role in mental health treatment within the psychedelic industry.
Psychedelic Alpha · Aug 26, 2026
Culture
Was Carlos Castaneda Among the First Psychedelic Grifters?
AI summary
The article explores whether Carlos Castaneda, a controversial figure in 20th-century spirituality, misrepresented his experiences with a Yaqui teacher, potentially using psychedelics as a vehicle for personal gain. It questions the authenticity of his accounts, suggesting he may have fabricated elements of his narrative to capitalize on the psychedelic movement's cultural moment. The piece highlights ongoing debates about the intersection of mysticism, exploitation, and the legacy of early psychedelic exploration.
DoubleBlind · Aug 26, 2026
Policy
Who Gets to Heal?
AI summary
The article "Who Gets to Heal?" from Psychedelics Today examines disparities in access to psychedelic therapies, highlighting systemic barriers such as socioeconomic inequality, racial bias, and lack of insurance coverage that limit marginalized communities' ability to benefit from these treatments. It underscores the urgent need for policy reforms and equitable distribution of resources to ensure psychedelic healing is accessible to all, not just those with financial privilege. The piece calls for industry stakeholders to prioritize inclusivity and address historical inequities in mental health care.
Psychedelics Today · Aug 25, 2026
Culture
Queering Psychedelics
AI summary
The article "Queering Psychedelics" from Chacruna explores the increasing integration of LGBTQ+ perspectives into psychedelic research and practice, emphasizing the role of queer narratives in redefining cultural, spiritual, and therapeutic frameworks within the field. It highlights the importance of creating inclusive spaces that honor diverse identities and experiences, advocating for intersectional approaches to ensure equity and representation in psychedelic education and healing. The piece underscores the transformative potential of queer-led initiatives in shaping a more holistic and accessible psychedelic movement.
Chacruna · Aug 25, 2026
Policy
Weekly Psychedelic Policy Briefing: August 23, 2026
AI summary
The August 23, 2026, Psychedelic Policy Briefing highlights recent legislative updates, including federal and state-level advancements in psychedelic research regulation and decriminalization efforts, alongside FDA guidance on clinical trial protocols. Key developments emphasize expanding access to therapeutic applications while addressing safety and oversight frameworks. These policy shifts signal growing institutional support for psychedelics in healthcare and scientific innovation.
Psychedelics Today · Aug 24, 2026
Culture
Healing in Community: Reflections on Racial Trauma and Plant Medicine in Oaxaca
AI summary
The article explores how plant medicine practices in Oaxaca are being used to address racial trauma through community-based healing, emphasizing the integration of indigenous knowledge with modern therapeutic frameworks. It highlights the role of cultural context and collective rituals in fostering resilience and reconciliation. The piece underscores the potential of plant medicine as a tool for addressing systemic inequities and promoting intergenerational healing.
Chacruna · Aug 24, 2026
PsyWire is an independent psychedelic industry intelligence feed, aggregating the latest research, policy, culture, and business news from leading sources across the global psychedelic ecosystem.
Psygen Watch
Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets... Psychedelics Today
Categories
All
Research
Policy
Culture
Business
Today at a glance
100
Articles
0
Research
23
Policy
35
Business